Skip to main content

Table 3 Comparison of platelet VEGF and plasma sVEGFR-2 per treatment groups in the CENTAURO-2 trial

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Groups pg of VEGF/106platelets
Mean (range)
[n]
pg/mL of sVEGFR-2
Mean (range)
[n]
  Week 0 Week 13 Week 0 Week 13
Ag + V 1.21 (0.30–2.20)
[7]
0.61 (0.10–1.43)
[7] ns
9736 (6939–11724)
[7]
9792 (7427–11162)
[7] ns
Ag + 2 V 0.93 (0.55–1.46)
[7]
1.01 (0.08–3.29)
[7] ns
10455 (8116–12653)
[8]
10423 (7262–12882) [8] ns
2Ag + V 2.07 (0.11–8.19)
[8]
0.57 (0.22–2.05)
[8] p = 0.0244*
9736 (7078–12637)
[8]
9948 (9125–11098)
[8] ns
½Ag + Al 1.90 (0.90–3.64)
[8]
1.98 (0.63–3.54)
[8] ns
10228 (7555–12735)
[8]
9567 (7820–13372)
[8] ns
Ag + Al 1.58 (0.72–3.19)
[8]
1.06 (0.15–2.91)
[8] p = 0.0086**
10131 (8491–12223)
[8]
10296 (8611–13294) [8] ns
  1. The table summarizes the data per vaccine dose cohorts and the results of paired t-test (ns: non-significant; *p < 0.05; **p < 0.01). (n) number of patients